Glucocorticoid-induced osteoporosis in rheumatic diseases

Clinics

Volumn 65, Issue 11, 2010, Pages 1197-1205

  Pereira, Rosa Maria Rodrigues ^a   de Carvalho, Jozélio Freire ^a   Canalis, Ernesto ^b,c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

^c UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Bone mineral density; Fractures; Glucocorticoids; Osteoporosis; Rheumatic diseases

Indexed keywords

GLUCOCORTICOID;

BONE DENSITY; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FRACTURE; HUMAN; OSTEOPOROSIS; REVIEW; RHEUMATIC DISEASE;

BONE DENSITY; FRACTURES, BONE; GLUCOCORTICOIDS; HUMANS; OSTEOPOROSIS; RHEUMATIC DISEASES;

EID: 79251518589     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322010001100024     Document Type: Review

References (78)

1. Cutolo M, Seriolo B, Pizzorni C, Secchi ME, Soldano S, Paolino S, et al. Use of glucocorticoids and risk of infections. Autoimmun Rev. 2008;8:153-5, doi: 10.1016/j.autrev.2008.07.010.
2. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid- induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13:777-87, doi: 10.1007/s001980200108.
3. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007;18:1319-28, doi: 10.1007/s00198-007-0394-0.
4. Pereira RM, Delany AM, Canalis E. Cortisol inhibits the differentiation and apoptosis of osteoblasts in culture. Bone 2001;28:484-90, doi: 10.1016/S8756-3282(01)00422-7.
5. Yeap S, Fauzi A, Kong N, Halim A, Soehardy Z, Rahimah S, et al. Influences on bone mineral density in Malaysian premenopausal systemic lupus erythematosus patients on corticosteroids. Lupus 2009;18:178-81, doi: 10.1177/0961203308094995.
6. Mendoza-Pinto C, García-Carrasco M, Sandoval-Cruz H, Escárcega RO, Jiménez-Hernández M, Etchegaray-Morales I, et al. Risks factors for low bone mineral density in pre-menopausal Mexican women with systemic lupus erythematosus. Clin Rheumatol. 2009;28:65-70, doi: 10.1007/ s10067-008-0984-z.
7. Mok CC, Cheung MY, Ho LY, Yu KL, To CH. Risk and predictors of work disability in Chinese patients with systemic lupus erythematosus. Lupus. 2008;17:1103-7, doi: 10.1177/0961203308094280.
8. Almehed K, Forsblad d'Elia H, Kvist G, Ohlsson C, Carlsten H. Prevalence and risk factors of osteoporosis in female SLE patientsextended report. Rheumatology Oxford. 2007;46:1185-90, doi: 10.1093/ rheumatology/kem105.
9. Chong HC, Chee SS, Goh EM, Chow SK, Yeap SS. Dietary calcium and bone mineral density in premenopausal women with systemic lupus erythematosus. Clin Rheumatol. 2007;26:182-5, doi: 10.1007/s10067-006-0258-6.
10. Lee C, Almagor O, Dunlop DD, Manzi S, Spies S, Chadha AB, et al. Disease damage and low bone mineral density: an analysis of women with systemic lupus erythematosus ever and never receiving corticosteroids. Rheumatology. (Oxford) 2006;45:53-60, doi: 10.1093/rheumatology/ kei079.
11. Borba VZ, Matos PG, da Silva Viana PR, Fernandes A, Sato EI, Lazaretti-Castro M. High prevalence of vertebral deformity in premenopausal systemic lúpus erythematosus patients. Lupus. 2005;14:529-33, doi: 10.1191/0961203305lu2154oa.
12. Bultink IE, Lems WF, Kostense PJ, Dijkmans BA, Voskuyl AE. Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum. 2005;52:2044-50, doi: 10.1002/art.21110.
13. Yee CS, Crabtree N, Skan J, Amft N, Bowman S, Situnayake D, et al. Prevalence and predictors of fragility fractures in systemic lupus erythematosus. Ann Rheum Dis. 2005;64:111-3, doi: 10.1136/ard.2003.018127.
14. Pineau CA, Urowitz MB, Fortin PJ, Ibanez D, Gladman DD. Osteoporosis in systemic lupus erythematosus: factors associated with referral for bone mineral density studies, prevalence of osteoporosis and factors associated with reduced bone density. Lupus. 2004;13:436-41, doi: 10.1191/0961203303lu1036oa.
15. Uaratanawong S, Deesomchoke U, Lertmaharit S, Uaratanawong S. Bone mineral density in premenopausal women with systemic lupus erythematosus. J Rheumatol 2003;30:2365-8.
16. Boyanov M, Robeva R, Popivanov P. Bone mineral density changes in women with systemic lupus erythematosus. Clin Rheumatol. 2003;22:318-23, doi: 10.1007/s10067-003-0743-0.
17. Bhattoa HP, Bettembuk P, Balogh A, Szegedi G, Kiss E. Bone mineral density in women with systemic lupus erythematosus. Clin Rheumatol. 2002;21:135-41, doi: 10.1007/s10067-002-8272-9.
18. Becker A, Fischer R, Scherbaum WA, Schneider M. Osteoporosis screening in systemic lupus erythematosus: impact of disease duration and organ damage. Lupus. 2001;10:809-14, doi: 10.1177/096120330101001108.
19. Bhattoa HP, Kiss E, Bettembuk P, Balogh A. Bone mineral density, biochemical markers of bone turnover, and hormonal status in men with systemic lupus erythematosus. Rheumatol Int. 2001;21:97-102, doi: 10.1007/s00296-001-0149-8.
20. Gilboe IM, Kvien TK, Haugeberg G, Husby G. Bone mineral density in systemic lupus erythematosus: comparison with rheumatoid arthritis and healthy controls. Ann Rheum Dis. 2000;59:110-5, doi: 10.1136/ard.59.2.110.
21. Kipen Y, Buchbinder R, Forbes A, Strauss B, Littlejohn G, Morand E. Prevalence of reduced bone mineral density in systemic lupus erythematosus and the role of steroids. J Rheumatol. 1997;24:1922-9.
22. Book C, Karlsson M, Akesson K, Jacobsson L. Disease activity and disability but probably not glucocorticoid treatment predicts loss in bone mineral density in women with early rheumatoid arthritis. Scand J Rheumatol. 2008;37:248-54, doi: 10.1080/03009740801998747.
23. Nampei A, Hashimoto J, Koyanagi J, Ono T, Hashimoto H, Tsumaki N, et al. Characteristics of fracture and related factors in patients with rheumatoid arthritis. Mod Rheumatol. 2008;18:170-6, doi: 10.1007/ s10165-008-0032-5.
24. Hämäläinen H, Kaarela K, Kröger H, Kauppi M, Järvenpää S, Hakala M, et al. Changes in bone mineral density in premenopausal women with rheumatoid arthritis during a two-year follow-up. Joint Bone Spine. 2007;74:482-7, doi: 10.1016/j.jbspin.2007.01.021.
25. Güler-Yüksel M, Bijsterbosch J, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Hulsmans HM, de Beus WM, et al. Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis. Ann Rheum Dis. 2008;67:823-8, doi: 10.1136/ard.2007.073817.
26. Silva RG, Pippa MG, Zerbini CA. Evaluation of body composition and bone mineral density in women with rheumatoid arthritis. Rev Assoc Med Bras. 2007;53:135-41, doi: 10.1590/S0104-42302007000200018.
27. Habib GS, Haj S. Bone mineral density in patients with early rheumatoid arthritis treated with corticosteroids. Clin Rheumatol. 2005;24:129-33, doi: 10.1007/s10067-004-0989-1.
28. Tourinho TF, Stein A, Castro JA, Brenol JC. Rheumatoid arthritis: evidence for bone loss in premenopausal women. J Rheumatol. 2005;32:1020-5.
29. van Everdingen AA, Siewertsz van Reesema DR, Jacobs JW, Bijlsma JW. Low-dose glucocorticoids in early rheumatoid arthritis: discordant effects on bone mineral density and fractures? Clin Exp Rheumatol. 2003;21:155-60.
30. de Nijs RN, Jacobs JW, Bijlsma JW, Lems WF, Laan RF, Houben HH, et al. Osteoporosis Working Group, Dutch Society for Rheumaology. Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritis. Rheumatology. (Oxford) 2001;40:1375-83, doi: 10.1093/rheumatology/40.12.1375.
31. Kroot EJ, Nieuwenhuizen MG, de Waal Malefijt MC, van Riel PL, Paskerde Jong PC, Laan RF. Change in bone mineral density in patients with rheumatoid arthritis during the first decade of the disease. Arthritis Rheum. 2001;44:1254-60, doi: 10.1002/1529-0131(200106)44:6<1254::AIDART216>3.0. CO;2-G.
32. Gilboe IM, Kvien TK, Haugeberg G, Husby G. Bone mineral density in systemic lupus erythematosus: comparison with rheumatoid arthritis and healthy controls. Ann Rheum Dis. 2000;59:110-5, doi: 10.1136/ard.59.2.110.
33. Cortet B, Flipo RM, Blanckaert F, Duquesnoy B, Marchandise X, Delcambre B. Evaluation of bone mineral density in patients with rheumatoid arthritis. Influence of disease activity and glucocorticoid therapy. Rev Rhum Engl Ed. 1997;64:451-8.
34. Hall GM, Spector TD, Griffin AJ, Jawad AS, Hall ML, Doyle DV. The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women. Arthritis Rheum. 1993;36:1510-6, doi: 10.1002/ art.1780361105.
35. Sambrook PN, Cohen ML, Eisman JA, Pocock NA, Champion GD, Yeates MG. Effects of low dose corticosteroids on bone mass in rheumatoid arthritis: a longitudinal study. Ann Rheum Dis. 1989;48:535-8, doi: 10.1136/ard.48.7.535.
36. Sambrook PN, Eisman JA, Yeates MG, Pocock NA, Eberl S, Champion GD. Osteoporosis in rheumatoid arthritis: safety of low dose corticosteroids. Ann Rheum Dis. 1986;45:950-3, doi: 10.1136/ard.45.11.950.
37. Als OS, Gotfredsen A, Christiansen C. The effect of glucocorticoids on bone mass in rheumatoid arthritis patients. Influence of menopausal state. Arthritis Rheum. 1985;28:369-75, doi: 10.1002/art.1780280403.
38. Valta H, Lahdenne P, Jalanko H, Aalto K, Mäkitie O. Bone health and growth in glucocorticoid-treated patients with juvenile idiopathic arthritis. J Rheumatol 2007;34:831-6.
39. Celiker R, Bal S, Bakkaloglu A, Ozaydin E, Coskun T, Cetin A, et al. Factors playing a role in the development of decreased bone mineral density in juvenile chronic arthritis. Rheumatol Int. 2003;23:127-9.
40. Cetin A, Celiker R, Dinçer F, Ariyürek M. Bone mineral density in children with juvenile chronic arthritis. Clin Rheumatol. 1998;17:551-3, doi: 10.1007/BF01451301.
41. Pereira RM, Corrente JE, Chahade WH, Yoshinari NH. Evaluation by dual X-ray absorptiometry (DXA) of bone mineral density in children with juvenile chronic arthritis. Clin Exp Rheumatol. 1998;16:495-501.
42. Varonos S, Ansell BM, Reeve J. Vertebral collapse in juvenile chronic arthritis: its relationship with glucocorticoid therapy. Calcif Tissue Int. 1987;41:75-8, doi: 10.1007/BF02555248.
43. Santiago RA, Silva CA, Caparbo VF, Sallum AM, Pereira RM. Bone mineral apparent density in juvenile dermatomyositis: the role of lean body mass and glucocorticoid use. Scand J Rheumatol. 2008;37:40-7, doi: 10.1080/03009740701687226.
44. Castro TC, Terreri MT, Szejnfeld VL, Len C, Fonseca AS, Hilário MO. Bone mineral density of Brazilian girls with juvenile dermatomyositis. Braz J Med Biol Res. 2005;38:309-13.
45. Stewart WA, Acott PD, Salisbury SR, Lang BA. Bone mineral density in juvenile dermatomyositis: assessment using dual x-ray absorptiometry. Arthritis Rheum. 2003;48:2294-8, doi: 10.1002/art.11211.
46. Regio P, Bonfá E, Takayama L, Pereira RM. The influence of lean mass in trabecular and cortical bone in juvenile onset systemic lupus erythematosus. Lupus. 2008;17:787-92, doi: 10.1177/0961203308089446.
47. Lilleby V, Lien G, Frey Frøslie K, Haugen M, Flatø B, et al. Frequency of osteopenia in children and young adults with childhood-onset systemic lupus erythematosus. Arthritis Rheum. 2005;52:2051-9, doi: 10.1002/art.21115.
48. Trapani S, Civinini R, Ermini M, Paci E, Falcini F. Osteoporosis in juvenile systemic lupus erythematosus: a longitudinal study on the effect of steroids on bone mineral density. Rheumatol Int. 1998;18:45-9, doi: 10.1007/s002960050056.
49. Kashef S, Saki F, Karamizadeh Z, Kashef MA. Bone mineral density in children wth systemic lupus erythematosus and juvenile rheumatoid arthritis. Ann Saudi Med. 2007;27:427-31, doi: 10.4103/0256-4947.51458.
50. Alsufyani KA, Ortiz-Alvarez O, Cabral DA, Tucker LB, Petty RE, et al. Bone mineral density in children and adolescents with systemic lupus erythematosus, juvenile dermatomyositis, and systemic vasculitis: relationship to disease duration, cumulative corticosteroid dose, calcium intake, and exercise. J Rheumatol. 2005;32:729-33.
51. (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva: World Health Organization; 1994. Technical Report Series, No. 843.
52. Official positions of the International Society for Clinical Densitometry Updated 2007. Available at www.iscd.org/Visitors/positions/OfficialPositionsText.cfm Accessed July 5, 2009.
53. Langsetmo L, Goltzman D, Kovacs CS, Adachi JD, Hanley DA, Kreiger N, et al. Repeat Low-Trauma Fractures Occur Frequently Among Men and Women who have Osteopenic Bone Mineral Density. J Bone Miner Res. 2009;24:1515-22, doi: 10.1359/jbmr.090319.
54. Khan AA, Bachrach L, Brown JP, Hanley DA, Josse RG, Kendler DL, et al. Standards and guidelines for performing central dual-energy X-ray absorptiometry in premenopausal women, men, and children. J Clin Densitom. 2004;51-63, doi: 10.1385/JCD:7:1:51.
55. Souza RB, Borges CT, Takayama L, Aldrighi JM, Pereira RM. Systemic sclerosis and bone loss: the role of the disease and body composition. Scand J Rheumatol. 2006;35:384-7, doi: 10.1080/03009740600704296.
56. Frediani B, Baldi F, Falsetti P, Acciai C, Filippou G, Spreafico A, et al. Clinical determinants of bone mass and bone ultrasonometry in patients with systemic sclerosis. Clin Exp Rheumatol. 2004;22:313-8.
57. Yuen SY, Rochwerg B, Ouimet J, Pope JE. Patients with scleroderma may have increased risk of osteoporosis. A comparison to rheumatoid arthritis and noninflammatory musculoskeletal conditions. J Rheumatol. 2008;35:1073-8.
58. Sampaio-Barros PD, Costa-Paiva L, Filardi S, Sachetto Z, Samara AM, Marques-Neto JF. Prognostic factors of low bone mineral density in systemic sclerosis. Clin Exp Rheumatol. 2005;23:180-4.
59. Healey JH, Paget SA, Williams-Russo P, Szatrowski TP, Schneider R, Spiera H, et al. A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica. Calcif Tissue Int. 1996;58:73-80, doi: 10.1007/ BF02529727.
60. Andersson R, Rundgren A, Rosengren K, Bengtsson BA, Malmvall BE, Mellström D. Osteoporosis after long-term corticosteroid treatment of giant cell arteritis. J Intern Med. 1990;227:391-5, doi: 10.1111/j.1365-2796.1990.tb00177.x.
61. Hatz HJ, Helmke K. Polymyalgia rheumatica and giant cell arteritis; diagnosis and side effects of low-dose long-term glucocorticoid therapy. Z Rheumatol 1992;51:213-21.
62. Pearce G, Ryan PF, Delmas PD, Tabensky DA, Seeman E. The deleterious effects of low-dose corticosteroids on bone density in patients with polymyalgia rheumatica. Br J Rheumatol. 1998;37:292-9, doi: 10.1093/ rheumatology/37.3.292.
63. (2001) American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum. 2001;44:1496-503, doi: 10.1002/1529-0131(200107)44: 7<1496::AID-ART271>3.0.CO;2-5.
64. Adler RA, Hochberg MC. Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs. Arch Intern Med. 2003;163:2619-24, doi: 10.1001/ archinte.163.21.2619.
65. Geusens PP, de Nijs RN, Lems WF, Laan RF, Struijs A, van Staa TP, et al. Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology. Ann Rheum Dis. 2004; 63:324-5, doi: 10.1136/ard.2003.008060.
66. National Osteoporosis Society & Royal College of Physicians guidelines working group for Bone and Tooth Society. Glucocorticoid-induced Osteoporosis: guidelines for prevention and treatment. London, Royal College of Physicians. 2002.
67. Saag KG, Gehlbach SH, Curtis JR, Youket TE, Worley K, Lange JL. Trends in prevention of glucocorticoid-induced osteoporosis. J Rheumatol. 2006;33:1651-7.
68. Guzman-Clark JR, Fang MA, Sehl ME, Traylor L, Hahn TJ. Barriers in the management of glucocorticoid-induced osteoporosis. Arthritis Rheum. 2007;57:140-6, doi: 10.1002/art.22462.
69. Solomon DH, Morris C, Cheng H, Cabral D, Katz JN, Finkelstein JS, et al. Medication use patterns for osteoporosis: an assessment of guidelines, treatment rates, and quality improvement interventions. Mayo Clin Proc. 2005;80:194-202, doi: 10.4065/80.2.194.
70. Berris KK, Repp AL, Kleerekoper M. Glucocorticoid-induced osteoporosis. Curr Opin Endocrinol Diabetes Obes. 2007;14:446-50.
71. Heaney RP. The vitamin D requirement in health and disease. J Steroid Biochem Mol Biol. 2005;97:13-9, doi: 10.1016/j.jsbmb.2005.06.020.
72. Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int. 2000;67:277-85, doi: 10.1007/s002230001146.
73. Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, doubleblind, double-dummy, randomised controlled trial. Lancet. 2009;373:1253-63, doi: 10.1016/S0140-6736(09)60250-6
74. Franchimont N, Canalis E. Management of glucocorticoid induced osteoporosis in premenopausal women with autoimmune disease. Autoimmun Rev. 2003;2:224-8, doi: 10.1016/S1568-9972(03)00056-9.
75. Djokanovic N, Klieger-Grossmann C, Koren G. Does treatment with bisphosphonates endanger the human pregnancy? J Obstet Gynaecol Can. 2008;30:1146-8.
76. Levy S, Fayez I, Taguchi N, Han JY, Aiello J, Matsui D, et al. Pregnancy outcome following in utero exposure to bisphosphonates. Bone. 2009;44:428-30, doi: 10.1016/j.bone.2008.11.001.
77. Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357:2028-39, doi: 10.1056/NEJMoa071408.
78. Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60:3346-55, doi: 10.1002/art.24879.